静脉泵入替罗非班对超出溶栓时间窗急性缺血性脑卒中的疗效分析

被引:33
作者
王乐园
贺爱荣
邵泽涛
尹丽丽
张倩倩
李彪
徐恩波
崔祥星
机构
[1] 山东省昌乐县人民医院神经介入科
关键词
急性缺血性脑卒中; 替罗非班; 溶栓时间窗;
D O I
暂无
中图分类号
R743.3 [急性脑血管疾病(中风)];
学科分类号
摘要
目的探讨经静脉注射替罗非班治疗超出溶栓时间窗急性缺血性脑卒中的有效性和安全性。方法选取超出溶栓时间窗急性脑卒中患者56例,随机分为治疗组和对照组各28例,对照组给予常规药物治疗,治疗组在常规药物治疗的基础上静脉泵入替罗非班治疗。根据NIHSS评分和改良Barthel指数量表对两组患者治疗前后的神经功能缺损程度及生活质量进行评价,评估两组治疗前及治疗后2、24小时及2周的NIHSS评分和神经功能缺损情况,治疗后2周使用BI指数量表评估日常生活自理能力。观察两组患者在治疗过程中出血等不良反应发生情况。结果两组基本资料、血清学检验指标差异无显著性。在治疗前两组比较NIHSS评分差异无显著性,治疗后2、24小时和2周时两组NIHSS评分均有所下降,与对照组比较,治疗组NIHSS评分下降更为明显。治疗组治疗后2周BI指数≥60百分比亦明显高于对照组(P<0.05)。治疗组症状明显改善、显效及总有效率均明显高于对照组,差异有显著性(P<0.05)。两组均无其他部位脑出血、消化道出血及需要输血的大出血的病例,梗死灶周围出血例数差异无显著性,治疗组皮肤、牙龈等部位出血发生率高于对照组。结论经静脉给予替罗非班能有效地控制急性脑梗死患者的临床症状,减轻神经功能缺损,提高日常生活能力评分,改善患者的预后。
引用
收藏
页码:546 / 549
页数:4
相关论文
共 13 条
  • [1] Outcome after stroke thrombolysis in patients >80 years treated within 3 hours vs >3–4.5 hours.[J].Niaz Ahmed;Kennedy R. Lees;Peter A. Ringleb;Christopher Bladin;David Collas;Danilo Toni;Gary A. Ford.Neurology.2017, 15
  • [2] Advanced age and higher national institutes of health stroke scale score as predictors of poor outcome in ischemic stroke patients treated with alteplase: A study from a tertiary care centre in rural North-west India.[J].Amit Bhardwaj;Girish Sharma;Sunil Raina;Ashish Sharma;Monica Angra.Journal of Neurosciences in Rural Practice.2017, 2
  • [3] Reciprocal Interaction of 24-Hour Blood Pressure Variability and Systolic Blood Pressure on Outcome in Stroke Thrombolysis
    Kellert, Lars
    Hametner, Christian
    Ahmed, Niaz
    Rauch, Geraldine
    MacLeod, Mary J.
    Perini, Francesco
    Lees, Kennedy R.
    Ringleb, Peter A.
    [J]. STROKE, 2017, 48 (07) : 1827 - +
  • [4] Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in Aged and Comorbid Mice With Acute Experimental Stroke
    Kraft, Peter
    Schuhmann, Michael K.
    Fluri, Felix
    Lorenz, Kristina
    Zernecke, Alma
    Stoll, Guido
    Nieswandt, Bernhard
    Kleinschnitz, Christoph
    [J]. STROKE, 2015, 46 (12) : 3502 - 3506
  • [5] Endovascular Reperfusion Strategies for Acute Stroke
    Papanagiotou, Panagiotis
    White, Christopher J.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (04) : 307 - 317
  • [6] Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation.[J].Amber B. Ouweneel;Miranda Van Eck.Vascular Pharmacology.2016,
  • [7] Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.[J].Shawn King;Marintha Short;Cassidy Harmon.Vascular Pharmacology.2016,
  • [8] Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China Analysis of the Results From the Chinese National Stroke Registry (CNSR)
    Wang, Yilong
    Liao, Xiaoling
    Zhao, Xingquan
    Wang, David Z.
    Wang, Chunxue
    Nguyen-Huynh, Mai N.
    Zhou, Yong
    Liu, Liping
    Wang, Xianwei
    Liu, Gaifen
    Li, Hao
    Wang, Yongjun
    [J]. STROKE, 2011, 42 (06) : 1658 - 1664
  • [9] Current Status of Endovascular Stroke Treatment
    Meyers, Philip M.
    Schumacher, H. Christian
    Connolly, E. Sander, Jr.
    Heyer, Eric J.
    Gray, William A.
    Higashida, Randall T.
    [J]. CIRCULATION, 2011, 123 (22) : 2591 - 2601
  • [10] The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions
    Seitz, RJ
    Meisel, S
    Moll, M
    Wittsack, HJ
    Junghans, U
    Siebler, M
    [J]. NEUROLOGY, 2004, 62 (11) : 2110 - 2112